The specialty pharmaceutical company has two proprietary product candidates in late-stage development, sumatriptan DosePro for acute migraine and ZX002 for chronic pain. Additionally, Zogenix is engaged in developing therapeutic solutions for rare CNS disorders and medical conditions, including Fintepla for Dravet syndrome and MT-1621 for TK2d. The company operates in a single operating segment and was recently acquired by UCB.